Ipratropiumbromid Teva (Ipratropium Bromide Monohydrate)

Ipratropium bromide works by competitively blocking muscarinic M3 receptors on airway smooth muscle. This inhibition prevents acetylcholine‑mediated contraction, leading to relaxation of bronchial muscles and reduced mucus secretion, which together improve airflow and ease breathing.

The dosage is individualized; the prescribing clinician determines the appropriate inhalation regimen based on the patient’s condition, severity, and response. No standard dose can be provided here, and patients should follow their healthcare provider’s instructions.

Safety data are limited. The medication should be used during pregnancy or lactation only if the potential benefit justifies any potential risk to the fetus or infant. Consultation with a qualified healthcare professional is essential before use in these situations.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Compared with short‑acting β2‑agonists, ipratropium offers a longer duration of action and a different mechanism, making it useful as add‑on therapy. Unlike long‑acting anticholinergics, it is typically used for maintenance and occasional rescue, providing a favorable safety profile for patients who may experience β‑agonist side effects.

The product should be stored at room temperature, below 25 °C, in its original container, protected from moisture and direct sunlight. Keep the inhalation device sealed when not in use to maintain drug stability.

Ipratropium bromide is delivered via a metered‑dose inhaler or nebulizer solution. The patient inhales the prescribed number of puffs or nebulized dose, usually using a spacer or mouthpiece, following the healthcare provider’s instructions for technique and timing.

Serious adverse reactions, though uncommon, can include severe allergic responses such as anaphylaxis, paradoxical bronchospasm, urinary retention, and exacerbation of narrow‑angle glaucoma. Patients should seek immediate medical attention if they experience difficulty breathing, facial or throat swelling, or sudden vision changes.

Individuals with a known hypersensitivity to ipratropium bromide or any formulation excipients, as well as patients with uncontrolled narrow‑angle glaucoma or urinary retention, should avoid using this product. Clinicians must evaluate contraindications before prescribing.